Flualprazolam
Flualprazolam is a benzodiazepine derivative which was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in Sweden in 2018. It can be described as the 2'-fluoro derivative of alprazolam, or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects.

Legal status 

Flualprazolam is banned in Sweden. In December 2019, the World Health Organization recommended flualprazolam for international scheduling under the Convention on Psychotropic Substances.